Abbott Posts 53-Cent Q3 EPS as Traders Await Full Results
ABT sits 23% above its 52-week low of $81.97.
Summary
Abbott reported third-quarter adjusted EPS of $1.42 and sales of $13.01B, with the initial wire flash having put EPS at 53 cents before the fuller figures. The company guided full-year adjusted EPS to $5.50 to $5.55 and fourth-quarter adjusted EPS to $1.62 to $1.67, and now sees 2026 comparable sales growth of about 6%, lowering its 2026 sales growth forecast on medical device weakness. Context matters here: Q2 2026 earnings dropped sharply on costs tied to the Exact Sciences acquisition even as revenue grew 13%, and legal costs remain elevated after the $670 million preterm formula settlement and the $384 million contaminated-formula resolution.
At the time of this announcement, ABT was trading at $100.52 on NYSE in the Life Sciences sector, with a market capitalization of approximately $177.3B. The 52-week trading range was $81.97 to $132.03. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.